Gefetinib
Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
National Cancer Institute (NCI)N/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cetuximab Fox Chase Cancer Center | Phase 1/2 | B |
Irinotecan National Cancer Institute (NCI) | Phase 1/2 | B |
Alvespimycin National Cancer Institute (NCI) | Phase 1 | CC |
Everolimus Fox Chase Cancer Center | Phase 1 | CC |
7-hydroxystaurosporine National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Gefetinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →